AVIDIO™ Platform

Virus-Like Vesicle Technology for Multi-Gene Delivery.

The AVIDIO™ Virus-Like Vesicle (VLV) platform was originally discovered at Yale School of Medicine by Professor John Rose — a foundational virologist whose prior work includes the rabies-based VSV vector platform. The technology was exclusively licensed to CaroGen Corporation, a Yale School of Medicine spin-off, and further developed into the AVIDIO™ delivery system powering CARG-2020.

1

Core manufacturing process

3

Tumor types validated

2044

IP protection through

Foundational Technology

What is a Virus-Like Vesicle?

A virus-like vesicle (VLV) is a non-replicating delivery vehicle combining the cellular entry efficiency of a viral system with the safety profile of a non-viral platform. VLVs deliver multiple therapeutic genes without the replication risk of oncolytic viruses or the payload limitations of lipid nanoparticles.

AVIDIO™'s defining capability: co-expressing multiple therapeutic genes from a single construct, in a single dose, at a single site — the core reason CARG-2020 can address three immune mechanisms simultaneously.

Competitive Positioning

AVIDIO™ vs. Alternative Delivery Technologies.

Every major oncology delivery approach carries a significant limitation. AVIDIO™ was engineered to overcome each of them.

Comparison

AVIDIO™ Advantage

vs. Oncolytic Viruses

Controlled, predictable expression with no viral replication propagation risk

vs. Non-Viral RNA / LNP

True multi-gene co-delivery with self-amplifying expression; no payload size ceiling

vs. CAR-T & TIL

Off-the-shelf manufacturing — no patient-specific production required

vs. Checkpoint Monotherapy

Addresses all three suppression axes simultaneously; active on immunologically "cold" tumors

Platform Features

Engineered for Multi-Mechanism Therapy.

Single construct delivers IL-12, dnIL-17RA, and PD-L1 shRNA — three suppression mechanisms in one dose.

Built-in amplification drives high transgene expression at the target site — transient by design, no genomic integration.

Designed for intraperitoneal and intratumoral administration, concentrating therapeutic effect where needed most and minimizing systemic toxicity.

Same core process supports every indication — no redevelopment required as the pipeline expands.

Intellectual Property & Development Status

Protected to 2044. Where CARG-2020 Stands Today.

Composition-of-matter patent covering the VLV platform. Issued March 2026. 18+ years of remaining exclusivity.

The strongest form of patent protection in pharmaceuticals — covers the platform itself, not just specific methods.

Same platform protection extends across all therapeutic applications, including future indications beyond the current pipeline.

Supplemental filings underway to extend protection across platform applications and pipeline expansion programs.

Development Status

Preclinical proof-of-concept: Complete tumor eradication and durable immune memory across three solid tumor models
Peer-reviewed publication: Alvero et al., Cancer Immunology Research, 2023. Chen et al., Acta Pharmaceutica Sinica B., 2024. Ahmadi et al., Scientific Reports, 2025
FDA Pre-IND meeting: Initiated — feedback informed design of IND-enabling studies
Manufacturing partner: Identified
Clinical site: Identified; IND-enabling studies defined
IP: U.S. Patent No. 12,577,585 issued March 2026 — protection to 2044

See the Platform in Action.

Preclinical validation data showing AVIDIO-delivered CARG-2020 efficacy across multiple tumor models.

Or explore the full pipeline